Back to today’s briefing

Story perspectives

Daiichi Sankyo, Merck Withdraw Lung Cancer Treatment Application

5/30/2025

27 5

Summary

Story summary

Daiichi Sankyo and Merck have made the difficult decision to withdraw their Biologics License Application for patritumab deruxtecan, a treatment for EGFR-mutated non-small cell lung cancer, following disappointing survival results from the HERTHENA-Lung02 Phase 3 trial. The companies plan to share these findings at the ASCO Annual Meeting on June 1, 2025.

1 of 1

Story summary

Daiichi Sankyo and Merck have made the difficult decision to withdraw their Biologics License Application for patritumab deruxtecan, a treatment for EGFR-mutated non-small cell lung cancer, following disappointing survival results from the HERTHENA-Lung02 Phase 3 trial. The companies plan to share these findings at the ASCO Annual Meeting on June 1, 2025.